FDA rejects Cumberland liver drug for second use
This article was originally published in Scrip
Executive Summary
Cumberland Pharmaceuticals took a beating on Wall Street Wednesday, with the Nashville, Tenn. firm’s shares losing as much as 16% of their value, after the US FDA rejected the company’s supplemental new drug application (sNDA) for Acetadote (acetylcysteine) as an injectable treatment for patients with non-acetaminophen-induced acute liver failure.